Interim report May – Oct 2022: Continued steady growth shows that we are on track to establish OPRA[TM] in the US
The period AUG 1st 2022 – Oct 31st 2022 ▪ Net sales amountedTSEK 20 226 (11 883), which is an increase of 70% compared with the corresponding period last year. The growth in the US market is 78% compared with the corresponding period last year. ▪ Operating profit amounted to TSEK 873 (-243) ▪ Net profit amounted to TSEK 2 320 (16 186) ▪ Cashflow from operating activities amounted to TSEK -1 032 (1 238) ▪ Earnings per share amounted to 0,13 SEK (0.90) Significant events in the quarter ▪ The number of hospitals offering the treatment continue to increase.